Sparsentan for the Treatment of VEGF Signaling Pathway Inhibitor-Associated Proteinuria

brief summary

Single-center, open-label, two-stage pilot study examining the efficacy and safety of sparsentan for reducing high-grade proteinuria among patients with cancer who receive vascular endothelial growth factor inhibitors